[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334345-105":59,"doc-detail-334345-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","transcription-factor-tcf7l1-targeting-hspb6-is-involved-in-emt-and-pi3kaktmtor-pathways-in-bladder-cancer","Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer","","Bladder cancer shows high recurrence and costly treatment, motivating identification of new therapeutic targets. The study centers on HSPB6, a small heat shock protein with reduced expression in bladder tumors, and evaluates its biological role using bioinformatics, RNA sequencing, and cell-based assays. HSPB6 upregulation suppresses proliferation and metastasis while promoting apoptosis. Mechanistically, TCF7L1-mediated HSPB6 increases inhibit the PI3K/AKT/mTOR signaling pathway, supporting HSPB6 as a promising bladder-cancer therapy target and regulator within this pathway.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/transcription-factor-tcf7l1-targeting-hspb6-is-involved-in-emt-and-pi3kaktmtor-pathways-in-bladder-cancer/334345/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/transcription-factor-tcf7l1-targeting-hspb6-is-involved-in-emt-and-pi3kaktmtor-pathways-in-bladder-cancer/334345.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic focus of the study?","Question",{"text":112,"@type":113},"The study focuses on HSPB6 as a potential therapeutic target in bladder cancer, based on its reduced expression in tumors and its functional impact on cancer biology.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does HSPB6 affect bladder cancer cells according to the findings?",{"text":117,"@type":113},"HSPB6 upregulation inhibits cancer cell proliferation and metastasis while promoting apoptosis.",{"name":119,"@type":110,"acceptedAnswer":120},"What signaling pathway is implicated in the TCF7L1-mediated effects?",{"text":121,"@type":113},"TCF7L1-mediated upregulation of HSPB6 suppresses the PI3K/AKT/mTOR signaling pathway, which is described as a key driver of cancer progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334345,1790526361,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","RESEARCH ARTICLE  \nTranscription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer  \nReceived for publication, March 26, 2024, and in revised form, November 6, 2024 Published, Papers in Press, November 26, 2024, [https://doi.org/10.1016/j.jbc.2024.108024](https://doi.org/10.1016/j.jbc.2024.108024)  \nZizhi Li 1,2, Junyi Li2, Qingfei Cao2, Tong Shen2, Yingjie Wang2, Haoyang He2, and Ming Tong 1,2, *  \nFrom the 1Department of Medicine, Soochow University, Soochow, Jiangsu, China; 2Department of Urology, The First Afﬁliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China  \nReviewed by members of the JBC Editorial Board. Edited by Paul Shapiro  \nBladder cancer is notorious for its high recurrence and costly treatment burden, prompting a search for novel therapeutic targets. Our study focuses on HSPB6, a small heat shock protein whose reduced expression in bladder cancer suggests a role in tumor biology. Using an integrative approach of bioinformatics, RNA sequencing, and cell-based assays, we show that HSPB6 upregulation inhibits cancer cell proliferation and metastasis while promoting apoptosis. Moreover, TCF7L1-mediated upregulation of HSPB6 leads to suppression of the PI3K/AKT/mTOR signaling pathway, a key driver of cancer progression. These results position HSPB6 as a compelling target for bladder cancer therapy, and its regulatory role in the PI3K/AKT/mTOR axis underscores its therapeutic potential. Our ﬁndings pave the way for future investigations into HSPB6-centered treatment strategies.  \nGlobally, bladder cancer (BLCA) is recognized as a signiﬁcant health threat and ranks as one of the top cancers. The GLOBOCAN 2020 statistics rank BLCA as the world’s 10th most prevalent cancer, with yearly estimates indicating 573,000 new cases and 213,000 fatalities. Notably, BLCA exhibits a higher incidence and mortality rate in men, where it ranks as the sixth leading cause of cancer-related deaths and occurrences, with male rates being roughly four times that of females (1). Urothelial carcinoma emerges as the most common BLCA subtype, notorious for its recurrent nature. BLCAis divided into non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) based on tumor invasion depth, with MIBC associated with an elevated risk of recurrence, metastasis, and, therefore, a poorer outcome (2). The primary methods for diagnosing BLCA include cystoscopy and biopsy analysis. Magnetic resonance imaging (MRI) is integral for tumor staging, playing a vital role in determining the most appropriate therapeutic strategies. In the case of NMIBC or low-grade urothelial carcinoma, the conventional treatment regimen involves transurethral resection of the bladder tumor (TURBT). This procedure involves removing the tumor and a margin of healthy tissue surrounding it. Following TURBT, additional treatments may be applied, including Bacillus Calmette-Guérin (BCG) therapy or  \n* For correspondence: Ming Tong, [tongming_mail@163.com](tongming_mail@163.com).  \ndirect chemotherapy instillation into the bladder (2, 3). In cases of MIBC or recurrent NMIBC, the recommendation shifts to radical cystectomy with urinary diversion, complemented by options such as neoadjuvant chemotherapy, immunotherapy, targeted therapy, and radiotherapy to enhance patient survival prospects (4).  \nIn recent years, with the emergence of novel molecular marker detection technologies for BLCA, along with the clinical application of new immunotherapeutic agents and targeted therapies, including Antibody-Drug Conjugates (ADCs), there has been a noticeable reduction in BLCA mortality rates. However, approximately 44% of NMIBC cases still experience local recurrence or progress to MIBC (5–8). Moreover, the treatment duration and cost for BLCA remain relatively high in the ﬁeld of oncology. Therefore, developing more efﬁcient, precise, and cost-effective molecular diagnostic and therapeutic approaches is of","cbCaidS1daeCIHJ3","https://ap.wps.com/l/cbCaidS1daeCIHJ3","pdf",7467474,16,"English","# Background\n## Bladder cancer burden and clinical management\n## Heat shock proteins and HSPB6 context\n# Study rationale and key findings\n## HSPB6 regulation and effects on cancer cells\n## TCF7L1/HSPB6 and PI3K/AKT/mTOR pathway suppression","[{\"question\":\"What is the main therapeutic focus of the study?\",\"answer\":\"The study focuses on HSPB6 as a potential therapeutic target in bladder cancer, based on its reduced expression in tumors and its functional impact on cancer biology.\"},{\"question\":\"How does HSPB6 affect bladder cancer cells according to the findings?\",\"answer\":\"HSPB6 upregulation inhibits cancer cell proliferation and metastasis while promoting apoptosis.\"},{\"question\":\"What signaling pathway is implicated in the TCF7L1-mediated effects?\",\"answer\":\"TCF7L1-mediated upregulation of HSPB6 suppresses the PI3K/AKT/mTOR signaling pathway, which is described as a key driver of cancer progression.\"}]","Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer | PDF",1790006326]